Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 3168 Uterine Cervical Neoplasms 2191 Endometrial Neoplasms 1334 Breast Neoplasms 819 Fallopian Tube Neoplasms 808 Carcinoma, Ovarian Epithelial 772 Neoplasms 540 Colorectal Neoplasms 439 Carcinoma, Non-Small-Cell Lung 420 Uterine Cervical Dysplasia 376 Pancreatic Neoplasms 363 Stomach Neoplasms 354 Prostatic Neoplasms 318 Lung Neoplasms 315 Melanoma 289 Uterine Neoplasms 239 Peritoneal Neoplasms 238 Neoplasm Metastasis 238 Vulvar Neoplasms 229 Urinary Bladder Neoplasms 225 Esophageal Neoplasms 225 Head and Neck Neoplasms 222 Sarcoma 219 Carcinoma, Renal Cell 214 Recurrence 213 Colonic Neoplasms 210 Papillomavirus Infections 206 Triple Negative Breast Neoplasms 191 Squamous Cell Carcinoma of Head and Neck 177 Vaginal Neoplasms 147

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × Gynecologic × Clear all

NCT06072781 2026-04-02

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡